Screener
Rigel Pharmaceuticals RIGL Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Total assets | $504,608 | $513,594 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,486 | $7,191 |
| Accrued compensation | 6,009 | 11,914 |
| Accrued research and development | 5,742 | 5,524 |
| Acquisition-related liabilities | 5,000 | 5,000 |
| Revenue reserves and refund liability | 28,080 | 27,716 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's accounts payable?
- Rigel Pharmaceuticals (RIGL) reported accounts payable of $4.49M in Q1 2026.
- How has Rigel Pharmaceuticals's accounts payable changed year-over-year?
- Rigel Pharmaceuticals's accounts payable increased by 13.5% year-over-year, from $3.95M to $4.49M.
- What is the long-term trend for Rigel Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's accounts payable has grown at a 14.2% compound annual growth rate (CAGR), from $3.71M to $7.19M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Rigel Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude